New stock news | The IPO prospectus of DeShi BioPort is invalid.

Hangzhou Desheng Biological Technology Co., Ltd. (referred to as Desheng Biology) submitted its Hong Kong stock prospectus for 6 months on June 29 and expired on December 29. At the time of submission, Huatai International was the exclusive sponsor. The prospectus shows that according to Frost & Sullivan data, iMedImageTM independently developed by Desheng Biology is the world's largest scale universal medical image pedestal model. It has been successfully commercialized and is recognized as the world's first commercial cross-modal medical image pedestal model.